Thao P. Le

Array ( [id] => 12681928 [patent_doc_number] => 20180119142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT [patent_app_type] => utility [patent_app_number] => 15/565838 [patent_app_country] => US [patent_app_date] => 2015-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15565838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10654677 [patent_doc_number] => 20160000819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-07 [patent_title] => 'Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes' [patent_app_type] => utility [patent_app_number] => 14/682891 [patent_app_country] => US [patent_app_date] => 2015-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 47465 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14682891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11620045 [patent_doc_number] => 20170130231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'NOVEL DOUBLE-STRANDED OLIGO RNA AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING FIBROSIS OR RESPIRATORY DISEASES' [patent_app_type] => utility [patent_app_number] => 15/301713 [patent_app_country] => US [patent_app_date] => 2015-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 17789 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15301713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10312749 [patent_doc_number] => 20150197751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-16 [patent_title] => 'RNAI EXPRESSION CONSTRUCTS' [patent_app_type] => utility [patent_app_number] => 14/673468 [patent_app_country] => US [patent_app_date] => 2015-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12262 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14673468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14551711 [patent_doc_number] => 10344300 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Nanotubes as carriers of nucleic acids into cells [patent_app_type] => utility [patent_app_number] => 14/662334 [patent_app_country] => US [patent_app_date] => 2015-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 79 [patent_no_of_words] => 12656 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14662334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13000405 [patent_doc_number] => 10023863 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-17 [patent_title] => Therapeutics with conformationally restricted monomers [patent_app_type] => utility [patent_app_number] => 14/623498 [patent_app_country] => US [patent_app_date] => 2015-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 12 [patent_no_of_words] => 30521 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14623498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11325199 [patent_doc_number] => 20160355811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => 'Antisense Oligonucleotides for Treatment of Spinal Muscular Atrophy' [patent_app_type] => utility [patent_app_number] => 15/117758 [patent_app_country] => US [patent_app_date] => 2015-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14262 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15117758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11873826 [patent_doc_number] => 09745584 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-29 [patent_title] => 'Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4' [patent_app_type] => utility [patent_app_number] => 14/618162 [patent_app_country] => US [patent_app_date] => 2015-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 27766 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14618162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10312751 [patent_doc_number] => 20150197753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-16 [patent_title] => 'Method for Generating Aptamers with Improved Off-Rates' [patent_app_type] => utility [patent_app_number] => 14/610758 [patent_app_country] => US [patent_app_date] => 2015-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 25765 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14610758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11895405 [patent_doc_number] => 09765332 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-19 [patent_title] => 'Oligonucleotides and methods for inhibiting or reducing bacterial biofilms' [patent_app_type] => utility [patent_app_number] => 15/113988 [patent_app_country] => US [patent_app_date] => 2015-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 19498 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15113988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311993 [patent_doc_number] => 20160348103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'Oligonucleotides and Methods for Treatment of Cardiomyopathy Using RNA Interference' [patent_app_type] => utility [patent_app_number] => 15/114063 [patent_app_country] => US [patent_app_date] => 2015-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 33217 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15114063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12946171 [patent_doc_number] => 09834767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-05 [patent_title] => Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 [patent_app_type] => utility [patent_app_number] => 14/582412 [patent_app_country] => US [patent_app_date] => 2014-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 21837 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14582412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10228680 [patent_doc_number] => 20150113670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-23 [patent_title] => 'Compositions and Methods for Inhibiting Expression of RRM2 Genes' [patent_app_type] => utility [patent_app_number] => 14/578716 [patent_app_country] => US [patent_app_date] => 2014-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 25006 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14578716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11364379 [patent_doc_number] => 20170002361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'SIRNA TARGETING PRK2, WHICH IS HEPATITIS C VIRUS THERAPEUTIC AGENT' [patent_app_type] => utility [patent_app_number] => 15/105516 [patent_app_country] => US [patent_app_date] => 2014-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 11452 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15105516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10209479 [patent_doc_number] => 20150094461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-02 [patent_title] => 'OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS' [patent_app_type] => utility [patent_app_number] => 14/570355 [patent_app_country] => US [patent_app_date] => 2014-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 136661 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14570355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11843397 [patent_doc_number] => 09730935 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-15 [patent_title] => 'Targeting a non-canonical notch signaling pathway for cancer treatment' [patent_app_type] => utility [patent_app_number] => 14/567834 [patent_app_country] => US [patent_app_date] => 2014-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 18049 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14567834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10209368 [patent_doc_number] => 20150094358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-02 [patent_title] => 'TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF' [patent_app_type] => utility [patent_app_number] => 14/566315 [patent_app_country] => US [patent_app_date] => 2014-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 26524 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14566315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10452289 [patent_doc_number] => 20150337303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-26 [patent_title] => 'METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION' [patent_app_type] => utility [patent_app_number] => 14/552436 [patent_app_country] => US [patent_app_date] => 2014-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40197 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14552436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10406951 [patent_doc_number] => 20150291960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-15 [patent_title] => 'MODULATION OF CD40 EXPRESSION' [patent_app_type] => utility [patent_app_number] => 14/542923 [patent_app_country] => US [patent_app_date] => 2014-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23709 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14542923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12347487 [patent_doc_number] => 09951332 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => SnoRNA, compositions and uses [patent_app_type] => utility [patent_app_number] => 15/035327 [patent_app_country] => US [patent_app_date] => 2014-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 43 [patent_no_of_words] => 14734 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15035327 [rel_patent_id] =>[rel_patent_doc_number] =>)